Drug Trial Radar · NCT05762276
A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Mar 7, 2023
Primary completion
Jul 25, 2024
Study completion Jul 25, 2024
Sponsor
- Lead sponsor
- Axxium Life, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Mar 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal dose regimen for LDL-C lowering in subsequent clinical trials.
Conditions
- Hypercholesterolemia
Interventions
VXX-401Drug
A synthetic PCSK9 peptide-based immunotherapy
PlaceboBiological
Normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of adverse eventsTime frame: 30 weeks
- ImmunogenicityTime frame: Baseline to Week 16, 20, 24, and 30
- ImmunogenicityTime frame: Baseline to Week 16, 20, 24, and 30
- Determine optimal VXX-401 dose regimenTime frame: Baseline to Week 16, 20, 24, and 30
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Northern Beaches Clinical Research
Brookvale, New South Wales, Australia
Sutherland Shire Clinical Research
Miranda, New South Wales, Australia
Emeritus Research
Sydney, New South Wales, Australia
University of the Sunshine Coast (USC)
Morayfield, Queensland, Australia
Emeritus Research
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.